The overall mission of the Virology/Immunology Core is to enhance HIV-related research and promote collaborations among HIV investigators, by providing improved access to virologic and immunologic assays, clinical specimens, and recombinant DMA constructs.
The specific aims of this Core are: 1. To provide a centralized repository for clinical specimens and HIV-related recombinant DMA constructs that can be used by clinical, behavioral, and laboratory investigators. 2. To centralize, and improve access to, state-of-the-art virologic assays for clinical, behavioral, and laboratory investigators. 3. To provide a centralized facility that produces recombinant proteins relevant to HIV research. 4. To provide expertise in the design and interpretation of flow cytometry assays, and to improve access to the shared instrumentation necessary to conduct these studies. 5. To provide improved access to existing URMC core facilities. This core will utilize and augment already existing infrastructures, such as those in the Cold Storage Facility (Aim 1), Infectious Diseases Unit laboratories (Aim 2), Human Immunology Center (Aim 4), and existing core facilities (Aim 5) at the URMC. In addition, we will centralize expression of certain recombinant proteins (Aim 3), in order to provide economy of scale to investigators that use them in HIVrelated research. The Virology/Immunology Core will implement the overall mission of the UR D-CFAR by supporting a broad base of investigators from the UR and its international collaborators in South Africa, and promoting interdisciplinary collaborations among them.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI078498-05
Application #
8377549
Study Section
Special Emphasis Panel (ZAI1-EC-A)
Project Start
2012-05-01
Project End
2013-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
5
Fiscal Year
2012
Total Cost
$133,059
Indirect Cost
$78,634
Name
University of Rochester
Department
Type
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Brewer, Matthew G; DiPiazza, Anthony; Acklin, Joshua et al. (2017) Nanoparticles decorated with viral antigens are more immunogenic at low surface density. Vaccine 35:774-781
Morse, Diane S; Wilson, John L; McMahon, James M et al. (2017) Does a Primary Health Clinic for Formerly Incarcerated Women Increase Linkage to Care? Womens Health Issues 27:499-508
Lu, Xin; Johnson, Brent A (2017) Direct estimation for adaptive treatment length policies: Methods and application to evaluating the effect of delayed PEG insertion. Biometrics 73:981-989
Hilimire, Thomas A; Chamberlain, Jeffrey M; Anokhina, Viktoriya et al. (2017) HIV-1 Frameshift RNA-Targeted Triazoles Inhibit Propagation of Replication-Competent and Multi-Drug-Resistant HIV in Human Cells. ACS Chem Biol 12:1674-1682
Liu, Yuhang; Zhang, Jinfeng; Qiu, Xing (2017) Super-delta: a new differential gene expression analysis procedure with robust data normalization. BMC Bioinformatics 18:582
Kushwaha, Sameer; Lalani, Yasmin; Maina, Geoffrey et al. (2017) ""But the moment they find out that you are MSM…"": a qualitative investigation of HIV prevention experiences among men who have sex with men (MSM) in Ghana's health care system. BMC Public Health 17:770
Singh, Vir B; Singh, Meera V; Piekna-Przybylska, Dorota et al. (2017) Sonic Hedgehog mimetic prevents leukocyte infiltration into the CNS during acute HIV infection. Sci Rep 7:9578
Hayashi, Tsuyoshi; Jean, Maxime; Huang, Huachao et al. (2017) Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription. Antiviral Res 146:76-85
Antwi, Sampson; Yang, Hongmei; Enimil, Anthony et al. (2017) Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection. Antimicrob Agents Chemother 61:
Piekna-Przybylska, Dorota; Sharma, Gaurav; Maggirwar, Sanjay B et al. (2017) Deficiency in DNA damage response, a new characteristic of cells infected with latent HIV-1. Cell Cycle 16:968-978

Showing the most recent 10 out of 159 publications